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Abstract In patients with large total blood volume
contrast material (CM) dilution decreases coronary
attenuation in CT coronary angiography (CTCA). As
increased blood volume is well paralleled by body
surface area (BSA) we assessed a BSA-adapted CM
protocol to compensate for dilution effects. Low-dose
CTCA with prospective ECG-triggering was per-
formed in 80 patients with a BSA-adapted CM
bolus ranging 40–105 ml and injection rate ranging
3.5–5.0 ml/s for a BSA of \1.70 to C2.5 m2. Eighty
control patients matched for BSA who had previously
undergone routine CTCA with a fixed CM protocol of
80 ml at 5 ml/s served as reference group. The
average vessel attenuation from the proximal right
(RCA) and the left main coronary artery (LMA) was
assessed. Correlation of BSA with vessel attenuation
was assessed in both groups. BSA-matching of all
patients was successful (BSA-adapted group 1.98 ±
0.15 m2, range 1.66–2.39 m2 versus reference group
1.98 ± 0.17 m2, range 1.59–2.38 m2; P = 0.74).
Mean CM bolus was significantly smaller in the
BSA-adapted versus the reference group (70.9 ± 14.1
vs. 80.0 ± 0 ml, P \ 0.001). There was no correla-
tion in the BSA-adapted group (r = -0.07, P = 0.53,
SEE = 0.15), while coronary attenuation was inver-
sely related to BSA in the reference group (r = -0.59,
P \ 0.001, SEE = 0.14). We have successfully
validated a BSA-adapted contrast material protocol
which results in a comparable coronary contrast
enhancement independent of individual BSA. This
was achieved despite a significant reduction in the
overall contrast material amount.
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Introduction
Coronary artery disease (CAD) is one of the major
causes of morbidity and mortality in western coun-
tries. Computed tomography coronary angiography
(CTCA) is a lately introduced non-invasive cardiac
imaging method, which has been shown to reliably
detect significant CAD (greater than 50% luminal
narrowing) [1]. Prospective ECG-triggering has
allowed to substantially reduce radiation dose of
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CTCA from about 15–20 mSv down to 1–3 mSv at
maintained image quality [2] and accuracy [3, 4] so
that the clinical acceptance of CTCA is growing.
Coronary vessel attenuation may affect the accuracy
of CTCA [5–7] as for an accurate detection of
coronary plaque an appropriate amount of contrast
material (CM) is needed. While coronary vessels can
not be differentiated properly from the surrounding
tissue with too little CM, coronary blooming artefacts
caused by too large CM amounts may hamper the
detection of coronary plaque.
The attenuation of coronary vessel is influenced by
the individual patients weight, height (expressed by
body mass index (BMI) and body surface area (BSA))
and cardiac output [8–13], as well as by technical
factors related to the type and iodine concentration of
the CM [7], the technique for bolus timing [6], the
injection volume and rate [14], and tube voltage [15].
Previous CTCA protocols [2, 16–18] did not adapt to
patients individual body mass or cardiac output.
Consequently, vessel attenuation in CTCA has been
shown to vary strongly [6–9], depending on BMI and
to affect the optimal detection of coronary plaque.
Recently a BMI adapted protocol was introduced in
order to reduce the impact of BMI on image noise.
However, coronary contrast remained subject to large
variations [19], presumably due to bolus dilution
depending on blood volume. As increased blood
volume is well paralleled by BSA we identified BSA
as the most promising parameter to be of potential
value for adjusting the contrast bolus in future
protocols. Therefore, we aimed at assessing a BSA-
adapted CM protocol to compensate for dilution
effects and the interindividual BSA-related differ-
ences in coronary attenuation.
Methods
Patients
Eighty patients underwent for clinical indication a
64-slice CTCA using prospective ECG-triggering
with a contrast material protocol adapted to BSA
(Table 1). For comparison, a control group of 80
patients matched for BSA were retrospectively
recruited from a pool of patients (n = 230) who
had previously undergone CTCA with prospective
ECG-gating and a fixed CM protocol of 80 ml.
Exclusion criteria for CTCA were: hypersensitivity to
iodinated CM, renal insufficiency (creatinine levels
[150 lmol/l), non-sinus rhythm, or haemodynamic
instability.
All 160 patients were referred for evaluation of
known (n = 23) or unknown CAD (n = 137), based
on symptoms such as dyspnoea (n = 18), typical
angina pectoris (n = 27), atypical chest pain
(n = 75), or without symptoms for pre-operative
rule-out of CAD in high-risk patients (n = 40).
The study protocol was approved by the institu-
tional review board (local ethics committee of the
University Hospital Zurich) and written informed
consent was obtained from each patient.
Body surface area (BSA)
Body surface area (BSA) is an index which is
widely used in clinical practice. For many clinical
purposes BSA is a better indicator of metabolic
mass than body weight because it is less affected by
abnormal adipose mass. To obtain the BSA (m2) we
divided the square root of (height 9 weight) by 60
as previously reported by Mosteller [20] as this is
the most widely used method recommended by
most authorities including the British Columbia
Cancer Agency for calculating chemotherapy dos-
age [21].
Data acquisition and image analysis
To achieve a target heart rate \65 bpm, intravenous
metoprolol (5–20 mg) (Beloc, AstraZeneca, London,
UK) was administered prior to the CTCA examina-
tion if necessary. Furthermore, all patients received
Table 1 Protocol for BSA-adapted contrast-material (CM)
bolus and flow rate
BSA (m2) CM bolus (ml) Flow rate (ml/s)
\1.70 40 3.5
1.70–1.79 45 4.0
1.80–1.94 60 4.0
1.95–2.04 80 4.5
2.05–2.14 80 5.0
2.15–2.24 85 5.0
2.25–2.49 95 5.0
C2.5 105 5.0
CM contrast-material, BSA body surface area
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2.5 mg isosorbiddinitrate sublingual (Isoket, Schwarz
Pharma, Monheim, Germany) 2 min prior to the scan
for which iodixanol (Visipaque 320, 320 mg/ml, GE
Heathcare, Buckinghamshire, UK) followed by 50 ml
saline solution was injected into an antecubital vein
via an 18-gauge catheter. Amount and flow rate of CM
were gradually increased (40–105 ml, 3.5–5.0 ml/s,
corresponding to an iodine delivery rate ranging from
1.1 to 1.6 g/s) to parallel increases in BSA in the
BSA-adapted scanning protocol group (Table 1),
while in the non-adapted scanning protocol group
the amount and flow rate of contrast material were
kept constant at 80 ml and 5 ml/s (iodine delivery rate
1.6 g/s). Bolus tracking was performed and image
acquisition was started as soon as the CM appeared in
the ascending aorta, where the region of interest was
placed.
All CTCA examinations were performed on a
64-slice LightSpeed VCT XT scanner (GE Health-
care) with prospective ECG-triggering, using the
following scanning parameters: slice acquisition
64 9 0.625 mm, smallest X-ray window (only 75%
of the RR-cycle), z-coverage 40 mm with an incre-
ment of 35 mm, gantry rotation time 350 ms. Tube
voltage and current were adapted to BMI as previ-
ously described [2] to avoid increases in noise due to
increased BMI (Table 2). The total effective radiation
dose was calculated by multiplying the dose length
product (provided by the scanner) times a conversion
factor (0.017 mSv/cGy/cm) as previously suggested
[22]. All images were analyzed on an external
workstation (AW 4.4, GE Healthcare).
Vessel attenuation (in Hounsfield units, HU) were
measured twice by two independent readers (A.P. and
L.H., both experience level 3 [23]) in the proximal
RCA and the LMA, which served as regions of
interest (ROI) drawn as large as possible, carefully
avoiding calcifications, plaques, and stenoses, as
previously described in detail [8]. The mean of the
measurements by both readers in both ROI’s was
defined as ‘‘coronary vessel attenuation’’ and used for
further analysis.
Statistical analysis
All statistical analysis was performed using SPSS
software (SPSS 15.0, Chicago, ILL, USA). Quanti-
tative variables were expressed as mean ± standard
deviation (SD), and categorical variables were
expressed as frequencies and percentages. Differ-
ences between the two groups regarding coronary
artery attenuation and amount of applied contrast
material were tested for significance by using Mann–
Whitney-U-tests. Linear regression analysis was
performed to correlate BSA and coronary artery
attenuation, and multiple regression analysis was
performed to compare this relationship between both
groups. Standard error of the estimate (SEE) was
determined. A P value of \0.05 was considered to
indicate statistical significance.
Results
CTCA was successfully performed in all 160
patients. Baseline characteristics of all patients
included in this study are given in Table 3. BSA-
matching of all patients was successful (BSA-adapted
Table 3 Patient baseline characteristics
Non-adapted
scanning
protocol
(n = 80)
BSA-adapted
scanning
protocol
(n = 80)
Female/male 21/59 12/68
Age (years) 59 ± 11 (34–82) 57 ± 11 (31–85)
BSA (m2) 1.98 ± 0.17
(1.59–2.38)
1.98 ± 0.15
(1.66–2.39)
Weight (kg) 82 ± 12 (55–115) 82 ± 12 (60–118)
Height (cm) 172 ± 8 (156–193) 174 ± 5 (149–183)
Heart rate (bpm) 56 ± 7 (36–74) 56 ± 7 (40–72)
BSA body surface area, bpm beats per minute
Table 2 Protocol for BMI-adapted tube parameters (accord-
ing to ref. 25)
BMI (kg/m2) Tube voltage (kV) Tube current (mA)
\22.5 100 450
22.5–24.9 100 500
25–27.4 120 550
27.5–29.9 120 600
30–40 120 650
[40 120 700
BMI body mass index
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group 1.98 ± 0.15 m2, range 1.66–2.39 m2 vs. ref-
erence group 1.98 ± 0.17 m2, range 1.59–2.38 m2;
P = n.s.).
As part of their baseline medication, 40 of 160
patients (25%) were on beta blocker treatment. To
achieve a target heart rate \65 bpm intravenous
metoprolol was given prior to CTCA in 103 patients
(64%). The mean dose length product from CTCA
was 139 ± 43 mGycm (range 65–318 mGycm)
resulting in an estimated mean effective radiation
dose of 2.4 ± 0.7 mSv (range 1.1–3.9 mSv).
Mean of the interobserver differences (between
L.H. and A.P.) in coronary artery attenuation mea-
surements was 7.0 ± 23.9 HU. In the BSA-adapted
group, mean attenuation values from both readers
were 378 ± 56 HU (range 262–490 HU) for LMA
and 363 ± 49 HU (range 260–510 HU) for RCA,
resulting in a mean coronary vessel attenuation of
370 ± 49 HU (range 268–500 HU). In the non-
adapted group, mean attenuation values were
424 ± 110 HU (range 280–712 HU) for LMA and
413 ± 103 HU (range 248–688 HU) for RCA,
resulting in a mean coronary vessel attenuation of
418 ± 104 HU (range 264–700 HU).
Coronary attenuation was inversely related to BSA
in the reference group (r = -0.59, P \ 0.001,
SEE = 0.14), while there was no correlation in the
BSA-adapted group (r = -0.07, P = n.s, SEE =
0.15) (Fig. 1).
The mean applied amount of CM was significantly
lower in the BSA-adapted versus the reference group
(70.9 ± 14.1 ml vs. 80.0 ± 0, P \ 0.001).
Discussion
The findings of the present study document that the
BSA-adapted CM administration protocol is feasible
and successful as the inverse correlation between
BSA and coronary attenuation found in our control
group, and also documented in previous reports [13,
19], could be abolished. As a result, range and
standard deviation of coronary attenuation were
smaller in the BSA-adapted group compared to the
control group indicating a well balanced consistent
contrast enhancement throughout a large range of
BSA (Fig. 2). Furthermore, by using the BSA-
adapted protocol a significantly lower average
amount of contrast medium was injected, which
may help preventing contrast induced nephropathy
and its sequelae [24]. Although the resulting average
coronary attenuation was slightly lower than in
controls, the range of coronary attenuation obtained
with our protocol (300–400 HU) compares well to the
values suggested by Becker et al. (250–300 HU) [5]
and Cademartiri et al. ([300 HU) [7] for adequate
coronary visualization and optimal stenosis detection
even in relatively small coronary arteries.
Fig. 1 Linear regression of body surface area against coronary
artery attenuation. Linear regression analysis (with 95%
confidence interval lines) of body surface area (BSA) against
coronary artery attenuation in the groups scanned with the
BSA-adapted protocol (left panel) and with the non-adapted
contrast material protocol (right panel). The significant inverse
correlation documented with the non-adapted protocol disap-
pears after adapting for BSA
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Attenuation of coronary vessel in CTCA is closely
related to several factors including patient specific
characteristics on one side such as body mass, blood
volume and cardiac output [8, 9, 11, 13] as well as
protocol related parameters on the other side such as
concentration and injection rate of the administered
CM [7, 19, 25]. In patients with increased body mass
CTCA image quality is degraded by an unfavorable
shift in the signal-to-noise ratio due to increase in
noise and loss of attenuation. Introduction of scan
protocols with body mass index-adapted tube current
and voltage have allowed to overcome the adverse
effects of body mass on image noise [25]. By
contrast, the adverse effect of body mass on coronary
attenuation is less well understood but recent reports
have suggested increased CM dilution due to higher
blood volume as explanation. Consequently, the
hypothesis has been generated that BSA would be
the most promising parameter to be used for CM
protocol adjustment [13, 19]. Our study provides the
evidence to approve this hypothesis. As our protocol
has included BMI adaptation of tube current and
voltage, our results suggest that an ideal protocol
should integrate both BMI adaptation of tube param-
eters (noise minimization) and CM adjustment
according to BSA (signal optimization). This may
help differentiating coronary plaque from surround-
ing tissue and avoid blooming artefacts caused by
excursive intracoronary CM concentration.
We acknowledge the following limitations to the
present study: First, the case matching of the control
group was retrospective, which may have introduced
bias. Second, the determination of the BSA-adapted
contrast material protocol was arbitrary. However, the
protocol was designed based on the upslope of the
coronary attenuation—BSA curve previously reported
[19]. Third, coronary attenuation was measured only
in two proximal vessels (RCA and LMA). However,
smaller vessel diameters of distal segments do not
allow appropriate placing of a ROI. Further studies in
larger populations are needed to confirm the added
value of greater consistency in coronary artery
attenuation regarding the accuracy of CTCA.
The proposed BSA-adapted contrast material pro-
tocol results in an adequate coronary vessel attenu-
ation independent of individual BSA.
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Fig. 2 CTCA images in patients with different body surface
area. CTCA images of patients with low (\1.8 m2), interme-
diate (1.8–2.2 m2) and high ([2.2 m2) body surface area
(BSA). Images of the BSA-adapted protocol show an equivalent
coronary attenuation independent of individual BSA (top row),
while differences in attenuation can be seen in the control group
depending on individual BSA (bottom row)
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